Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics

What are the safety and efficacy of finerenone in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) receiving background diuretics?In this prespecified secondary analysis of patients with HFmrEF/HFpEF in the FINEARTS-HF randomized clinical trial, the efficacy and safety of finerenone were consistent across subgroups defined by diuretic use, including those receiving only loop diuretics (≤40 mg and >40 mg of furosemide equivalent), only nonloop diuretics, and a combination of both. Finerenone reduced the need for loop diuretic dose intensification and decreased the mean loop diuretic dose compared to placebo.These findings demonstrate a diuretic-sparing effect of finerenone in patients with HFmrEF/HFpEF.

Corresponding Author: John J. V. McMurray, MD, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, United Kingdom (john.mcmurray@glasgow.ac.uk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.